Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus.
Head and neck cancers have been described in patients with human immunodeficiency virus-1 (HIV-1) infection. However the incidence, aetiology and clinical features of the disease remain unclear. Patients with head and neck cancer and HIV were identified from a large HIV centre. The incidence and clinical features were recorded, and the tumours were stained for Epstein-Barr virus (EBV). Head and neck cancer occurred more frequently than in an age-matched control group (1.66 vs 0.55/10,000 patient years respectively p < 0.05). Highly active anti-retroviral therapy has not significantly altered the incidence of the disease. All of the tumours tested were positive for EBV. Patients were moderately immunosuppressed at diagnosis and had aggressive tumours. All but one of the patients died of cancer with a median survival of 28 months. Head and neck cancer occurs more frequently in HIV. It is an aggressive disease and EBV may play a role in its pathogenesis.
Powles
T
T
Department of Oncology, Chelsea and Westminster Hospital, London, UK.
Powles
J
J
Nelson
M
M
Sandison
A
A
Peston
D
D
Buchannan
J
J
Mandalia
S
S
Gazzard
B
B
Bower
M
M
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003131:Combined Modality Therapy; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D015497:HIV-1; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000628:therapy / Q000821:virology*; D006801:Humans; D007111:Immunity, Cellular; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D012189:Retrospective Studies; D016896:Treatment Outcome